PYXS

Pyxis Oncology, Inc. Common Stock (PYXS) | Rumor.io

Pyxis Oncology

PYXS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,851

Bullish sentiment (50-day avg)41%

Price to earnings ratio-2.25

Market capitalization241.9M

Earnings per share-1.4

Dividend yield (TTM)—

Revenue (annual)13.9M

Net income (annual)-79.6M

Social

What share of all stock conversation is about PYXS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 9

PYXS's MICVO achieved a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR) in heavily pretreated patients.
The 5.4 mg/kg dose of PYXS's monotherapy demonstrated a 46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) in second-line or later patients.
PYXS's median overall survival (OS) is around 10.4 months, and a potential extension to 14+ months or 18 months would be a significant outcome.

Generated by AI

Sentiment

Of the messages about PYXS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	72% +42.15	67.56% -12.15
Bearish	—	0%	28% -42.15	32.44% +12.15

Bullish· Oct 9

$PYXS has a strong cash position with $90M in Q2, providing a runway into H2 2026.
The company's lead ADC candidate, pelidotin, is advancing in Ph1/2 trials with a KEYTRUDA combo, showing potential for significant revenue growth.
The recent appointment of a new SVP of IR & Capital Markets is expected to drive investor visibility and support the company's growth trajectory.

Bearish· Nov 22

The market may be overreacting to Pyxis Oncology's (PYXS) recent data, with some analysts seeing it as a "blurry biotech" with "so-so data".
The company's trading below cash, suggesting that management may need to buy back stock to demonstrate confidence in the company's prospects.
The stock's recent drop may be due to tax loss selling and the general "biotech blues," with some analysts predicting a potential move to $1.2 by year-end.

Generated by AI

Topics

Of the messages about PYXS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	94.02%	58.58%
Analysts	—	100%	5.13%	9.19%
Technical Analysis	—	0%	0%	32.06%
Earnings	—	0%	0.85%	0.17%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Announcements· Feb 27

Pyxis Oncology, Inc. (PYXS) has announced a $50 million private placement, with the company selling 8.85 million shares at $4.78 per share and pre-funded warrants to purchase 1.61 million shares at $0.001 per share.
The private placement is expected to close on or about February 29, 2024, and the net proceeds will be used to fund the continued development of PYX-201, the company's lead antibody-drug conjugate therapeutic candidate.
The financing includes participation from new and existing institutional investors, and the company anticipates the gross proceeds from the private placement to be approximately $50 million before deducting estimated fees and expenses.

Technical Analysis· Mar 31

$PYXS has shown an overextended condition but held up well, indicating potential support into the next week.
The stock's reversal is likely due to orders getting filled as people scoop up shares, potentially leading to a significant price increase.
A golden cross with an RSI reset has been observed in $PYXS, suggesting a potential long-term trend reversal.

Generated by AI

Community

Of the messages about PYXS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	69%	51.79%
Newcomers	—	100%	31%	48.21%

Regulars· Sep 9

The Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC) showed a confirmed objective response rate of 36% and a 12-month overall survival probability of 79%.
The updated data from the Phase 1 study revealed a manageable safety profile, with 94% disease control, but also showed peripheral neuropathy in almost every patient, which may impact the drug's use.
The FDA has approved the company's NDA, opening U.S. market access, and the company is planning to file an EMA marketing-authorization application, potentially leading to a future European launch.

Newcomers· Sep 9

Newcomers are focused on the positive Phase 1 data for Pyxis Oncology's MICVO, which showed rapid and deep responses in heavily pretreated patients, with a 36% confirmed objective response rate and 94% disease control rate.
The updated data has reinforced readiness to design a future trial, and is supported by regulatory feedback from FDA/EMA, indicating a potential path forward for the asset.
Newcomers are also tracking the median overall survival (OS) metric, which is around 10.4 months on average, with potential for extension to 14+ months or 18 months, which could be a significant catalyst for the asset.

Generated by AI

News

Pyxis Oncology stock falls on public offering announcement

14h agoYahoo Finance

Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Pyxis Oncology (PYXS)

Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

18d agoThe Globe and Mail

Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery (NASDAQ:PYXS)

Pyxis Oncology receives a "Sell" rating due to high risk, an unproven pipeline, and looming cash constraints. Click here to read more on PYXS.

18d agoSeeking Alpha

Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Pyxis Oncology (PYXS)

Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.

19d agoThe Globe and Mail

Pyxis Oncology stock price target raised to $8 by H.C. Wainwright

19d agoInvesting.com

Wells Fargo raises Pyxis Oncology stock price target on MICVO data

20d agoInvesting.com

Also Discussed

Investors talking about PYXS also mention

#	Name	Attention
1	Pharvaris N.V. Ordinary SharesPHVS	0%0
2	Guardforce AI Co., Ltd.GFAI	0%0
3	RPTX - Repare Therapeutics Inc.	——
4	Oric Pharmaceuticals, Inc.ORIC	0%0
5	Phibro Animal Health Corporation Class A Common StockPAHC	0%0
6	Phathom Pharmaceuticals, Inc.PHAT	0%new
7	OMIC - Singular Genomics Systems, Inc.	——
8	Apollomics Inc.APLM	0%0
9	Praxis Precision Medicines, Inc.PRAX	0%0
10	UHG - United Homes Group, Inc.	——

Pyxis Oncology, Inc. Common Stock

Healthcare
Biotechnology

Pyxis Oncology, Inc. Common Stock represents the equity of Pyxis Oncology, a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with an emphasis on solid tumors. The company’s current pipeline centers on antibody-drug conjugates and immuno-oncology programs designed to directly attack tumor cells and help overcome immune suppression in cancer. Its lead programs include micvotabart pelidotin, an investigational antibody-drug conjugate, along with additional candidates such as PYX-106 and PYX-107 that explore different mechanisms for targeting advanced cancers. Pyxis Oncology works across oncology research, clinical development, and translational medicine to advance product candidates intended for patients with limited treatment options. Headquartered in Boston, Massachusetts, Pyxis Oncology operates as part of the biotechnology sector and contributes to the broader development of precision cancer therapeutics.

Website

Location

321 Harrison Avenue

Boston, MA, 02118

United States

Social

What share of all stock conversation is about PYXS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 9

PYXS's MICVO achieved a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR) in heavily pretreated patients.
The 5.4 mg/kg dose of PYXS's monotherapy demonstrated a 46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) in second-line or later patients.
PYXS's median overall survival (OS) is around 10.4 months, and a potential extension to 14+ months or 18 months would be a significant outcome.

Generated by AI

Sentiment

Of the messages about PYXS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	72% +42.15	67.56% -12.15
Bearish	—	0%	28% -42.15	32.44% +12.15

Bullish· Oct 9

$PYXS has a strong cash position with $90M in Q2, providing a runway into H2 2026.
The company's lead ADC candidate, pelidotin, is advancing in Ph1/2 trials with a KEYTRUDA combo, showing potential for significant revenue growth.
The recent appointment of a new SVP of IR & Capital Markets is expected to drive investor visibility and support the company's growth trajectory.

Bearish· Nov 22

The market may be overreacting to Pyxis Oncology's (PYXS) recent data, with some analysts seeing it as a "blurry biotech" with "so-so data".
The company's trading below cash, suggesting that management may need to buy back stock to demonstrate confidence in the company's prospects.
The stock's recent drop may be due to tax loss selling and the general "biotech blues," with some analysts predicting a potential move to $1.2 by year-end.

Generated by AI

Topics

Of the messages about PYXS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	94.02%	58.58%
Analysts	—	100%	5.13%	9.19%
Technical Analysis	—	0%	0%	32.06%
Earnings	—	0%	0.85%	0.17%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Announcements· Feb 27

Pyxis Oncology, Inc. (PYXS) has announced a $50 million private placement, with the company selling 8.85 million shares at $4.78 per share and pre-funded warrants to purchase 1.61 million shares at $0.001 per share.
The private placement is expected to close on or about February 29, 2024, and the net proceeds will be used to fund the continued development of PYX-201, the company's lead antibody-drug conjugate therapeutic candidate.
The financing includes participation from new and existing institutional investors, and the company anticipates the gross proceeds from the private placement to be approximately $50 million before deducting estimated fees and expenses.

Technical Analysis· Mar 31

$PYXS has shown an overextended condition but held up well, indicating potential support into the next week.
The stock's reversal is likely due to orders getting filled as people scoop up shares, potentially leading to a significant price increase.
A golden cross with an RSI reset has been observed in $PYXS, suggesting a potential long-term trend reversal.

Generated by AI

Community

Of the messages about PYXS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	69%	51.79%
Newcomers	—	100%	31%	48.21%

Regulars· Sep 9

The Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC) showed a confirmed objective response rate of 36% and a 12-month overall survival probability of 79%.
The updated data from the Phase 1 study revealed a manageable safety profile, with 94% disease control, but also showed peripheral neuropathy in almost every patient, which may impact the drug's use.
The FDA has approved the company's NDA, opening U.S. market access, and the company is planning to file an EMA marketing-authorization application, potentially leading to a future European launch.

Newcomers· Sep 9

Newcomers are focused on the positive Phase 1 data for Pyxis Oncology's MICVO, which showed rapid and deep responses in heavily pretreated patients, with a 36% confirmed objective response rate and 94% disease control rate.
The updated data has reinforced readiness to design a future trial, and is supported by regulatory feedback from FDA/EMA, indicating a potential path forward for the asset.
Newcomers are also tracking the median overall survival (OS) metric, which is around 10.4 months on average, with potential for extension to 14+ months or 18 months, which could be a significant catalyst for the asset.

Generated by AI

Pyxis Oncology

Social

Sep 9

Bullish· Oct 9

Bearish· Nov 22

Announcements· Feb 27

Technical Analysis· Mar 31

Regulars· Sep 9

Newcomers· Sep 9

Pyxis Oncology stock falls on public offering announcement

Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Pyxis Oncology (PYXS)

Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery (NASDAQ:PYXS)

Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Pyxis Oncology (PYXS)

Pyxis Oncology stock price target raised to $8 by H.C. Wainwright

Wells Fargo raises Pyxis Oncology stock price target on MICVO data

Also Discussed

Pyxis Oncology, Inc. Common Stock

Company Information

Location

Pyxis Oncology stock falls on public offering announcement

Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Pyxis Oncology (PYXS)

Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery (NASDAQ:PYXS)

Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Pyxis Oncology (PYXS)

Pyxis Oncology stock price target raised to $8 by H.C. Wainwright

Wells Fargo raises Pyxis Oncology stock price target on MICVO data

Also Discussed

Social

Sep 9

Bullish· Oct 9

Bearish· Nov 22

Announcements· Feb 27

Technical Analysis· Mar 31

Regulars· Sep 9

Newcomers· Sep 9